Cleveland Clinic CEO named to panel of Trump advisers

Toby Cosgrove, MD, the longtime CEO and president of Cleveland Clinic, will sit on a non-partisan 16-member panel of business leaders offering expertise on job and economic growth to President-elect Donald Trump.

The President's Strategic and Policy Forum is expected to meet for the first time in February.

“I am truly honored and privileged to take part in President-elect Donald Trump's Strategic and Policy Forum designed to grow and strengthen the United States' economy,” Cosgrove said in a statement. “I applaud his efforts to bring together leaders across industries to gain insight that will assist the new President in making important decisions that will impact every American. I am deeply committed and take this role very seriously.”

Cosgrove’s fellow members will include former General Electric CEO Jack Welch, IBM Chairman Ginni Rometty and JPMorgan Chase CEO Jamie Dimon.

"This forum brings together CEOs and business leaders who know what it takes to create jobs and drive economic growth," Trump said in a press release. "My administration is committed to drawing on private sector expertise and cutting the government red tape that is holding back our businesses from hiring, innovating, and expanding right here in America."

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.